Outcome Analysis for Minimally Invasive Spine Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Prospective/Retrospective data analysis, chart reviews and clinical outcomes of minimally invasive spine surgery
| Condition |
|---|
|
Degenerative Disc Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | Outcome Analysis for Minimally Invasive Spine Surgery |
- Visual analog scale (VAS) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Pre-operative pain scores will be compared to the latest follow-up pain scores.
- Fusion on CT imaging or flexion-extension radiographs. [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]A board certified Neuro-radiologist will assess the fusion rate.Fusion will be determined by the presence of bony bridging on 2 consecutive sections in at least 2 planes on computed tomographic imaging.
- Oswestry Disability Index (ODI) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Pre-operative scores will be compared to the latest follow-up scores.
- Neck Disability Index (NDI) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Pre-operative scores will be compared to the latest follow-up scores.
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Spinal fusion patients with MIS surgery
Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
|
Detailed Description:
STUDY RATIONALE AND PRIMARY OBJECTIVE/HYPOTHESIS To assess the clinical and radiographic outcome of spinal fusion procedures using Silicate-Substituted Calcium Phosphate (Si-CaP), a newer-generation of synthetic ceramics designed to maximize osteoinduction and osteoconduction.
STUDY DESIGN Retrospective Study
PURPOSE OF THE STUDY Providing compelling evidence for the efficacy of Si-CaP in terms of resulting in satisfactory fusion.
SUMMARY OF METHODS A prospectively collected database will be reviewed retrospectively, to retrieve data of 200 patients who have undergone different spinal fusion procedures using Silicate-Substituted Calcium Phosphate (Si-CaP). An average follow up duration of at least 12 months will be considered. Clinical outcomes will be assessed using the visual analog scale (VAS), Oswestry Disability Index (ODI), and Neck Disability Index (NDI). Pre-operative scores will be compared to the latest follow-up scores. A board certified Neuro-radiologist will assess the fusion rate. Fusion will be determined by the presence of bony bridging on 2 consecutive sections in at least 2 planes on computed tomographic imaging.
SECONDARY ENDPOINTS AND EXPECTED RESULTS The purpose of this study is to evaluate the level of clinical and radiographic improvement in patients implanted with Silicate-Substituted Calcium Phosphate (Si-CaP) as a bone graft substitute material for spinal fusions. More comprehensive long term studies will be able to provide compelling evidence for the efficacy of Si-CaP in terms of resulting in satisfactory fusion. They can more strongly support the previously published data implying that Si-CaP can be utilized as an alternative to autogenous bone graft in spinal arthrodesis procedures.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Our prospectively collected institutional database will be reviewed to identify all consecutive patients with spinal fusion procedures using Silicate-Substituted Calcium Phosphate (Actifuse®, Baxter, Deerfield, IL) as a bone graft substitute. Surgeries have been performed at our hospital between 2007 and 2011. The estimated number of patients enrolled in the study is 200 patients. Patient demographics will be extracted using the database. The study population are from different age, gender and ethnicity groups. The indications for surgery will be recorded for each patient, as well. Institutional Research Board approval has been granted. All patients have provided informed consent for data collection regarding their treatment and outcomes.
Inclusion Criteria:
- Patients with different spinal fusion procedures (including AxiaLIF (axial lumbar interbody fusion), TLIF (transforaminal lumbar interbody fusion), ELIF (extreme lateral interbody fusion), PCF (posterior cervical fusion), and ACDF (anterior discectomy and fusion)) using Silicate-Substituted Calcium Phosphate (Actifuse®, Baxter, Deerfield, IL) as a bone graft substitute.
Exclusion Criteria:
- Utilization of any other bone extenders in addition to Si-CaP as a bone graft substitute.
Contacts and Locations| United States, New York | |
| Weill Cornell Brain and Spine Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Roger Härtl, MD 212-746-5543 roger@hartlmd.net | |
| Principal Investigator: Roger Härtl, MD | |
| Principal Investigator: | Roger Härtl, MD | Weill Cornell Neurological Surgery Department |
More Information
Additional Information:
Publications:
| Responsible Party: | Weill Medical College of Cornell University |
| ClinicalTrials.gov Identifier: | NCT01751841 History of Changes |
| Other Study ID Numbers: | 0806009851 |
| Study First Received: | November 7, 2012 |
| Last Updated: | December 13, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Intervertebral Disk Degeneration Spinal Diseases Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 23, 2013